ArticleJAMA dermatology2019

Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.

Nick Zimmermann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.